Merus (Netherlands)

Merus (Netherlands) is a company located in Utrecht, Netherlands.

Merus (Netherlands) is a company in Utrecht, Netherlands.

• 2022.02.28

  Reported2022.02.28

  Merus reports fourth-quarter and full-year 2021 results[2]Merus公布2021年第四季度及全年业绩finanznachrichten.de

  Merus announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update. The release reported that Merus ended 2021 with $430.7 million in cash, cash equivalents and marketable securities.

• 2022.02

  Reported2022.02.28

  Merus appoints Shannon Campbell chief commercial officer[2]Merus公布2021年第四季度及全年业绩finanznachrichten.de

  Merus appointed Shannon Campbell as executive vice president and chief commercial officer in February 2022. The source says she will lead the commercial strategy for Merus's most advanced clinical candidate, Zeno, and its pipeline of multispecific product candidates.

• 2020.05.14

  Reported2020.05.14

  Merus announces it will not continue MCLA-117 dose-expansion enrollment[3]Merus宣布不再继续MCLA-117剂量扩展队列的入组finanznachrichten.de

  Merus reported limited clinical activity for MCLA-117 and announced that it would not continue enrollment in the trial's planned dose-expansion cohorts. It said findings from the trial would inform development of its CD3 T-cell engager platform.

• 2019.11.05

  Reported2019.11.05

  Merus prices public offering of common shares[4]Merus为普通股公开发行定价finanznachrichten.de

  Merus announced the pricing of an underwritten public offering of 4,750,000 common shares at $14.50 per share and granted underwriters a 30-day option to purchase additional shares. The offering was expected to close on or about November 7, 2019, subject to customary closing conditions.

Read more

1. 1Merus (Netherlands)wikidata.org
2. 2Merus公布2021年第四季度及全年业绩finanznachrichten.de
3. 3Merus宣布不再继续MCLA-117剂量扩展队列的入组finanznachrichten.de
4. 4Merus为普通股公开发行定价finanznachrichten.de